araag2/HINT huggingface dataset:
Clinical trial NCT00537680 (phase 3, status: completed)
Conditions: friedreich's ataxia
ICD codes: G11.11
Drugs: idebenone, idebenone, placebo
SMILES: COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O, COC1=C(OC)C(=O)C(CCCCCCCCCCCCO)=C(C)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Documented diagnosis of Friedreich's Ataxia (FRDA) with confirmed FRDA mutations

          -  Patients 8 - 17 years of age at baseline

          -  Patients with a body weight greater than 25 kg/55 lbs at baseline

          -  Patients able to walk at least 10 meters without accompanying person (ICARS Walking
             Capacities score ≤6) at screening and baseline

          -  Patients who in the opinion of the investigator are able to comply with the
             requirements of the study, including swallowing the study medication

          -  Negative urine pregnancy test at screening and baseline (female patients of
             childbearing potential)

        Exclusion criteria:

          -  Treatment with idebenone, Coenzyme Q10 or vitamin E (if taken at a dose 5 times above
             the daily requirement) within the past month

          -  Patients with International Cooperative Ataxia Rating Scale (ICARS) score of greater
             than 54 or less than 10 at screening

          -  Pregnancy and/or breast-feeding

          -  Clinically significant abnormalities of clinical hematology or biochemistry including,
             but not limited to, elevations greater than 1.5 times the upper limit of normal of
             Aspartate Aminotransferase (AST; also known as GOT), Alanine Aminotransferase (ALT;
             also known as GPT) or creatinine

          -  History of abuse of drugs or alcohol

          -  Participation in the previous (Phase II) study of idebenone at the National Institutes
             of Health (NIH)

          -  Participation in a trial of another investigational drug within the last 3 months
Clinical trial NCT01569841 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 1
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin degludec, insulin glargine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 diabetes

          -  HbA1c (glycosylated haemoglobin) below or equal to 8.5%

          -  Current treatment with IGlar (insulin glargine) in a basal-bolus regimen with a total
             daily dose below 120 U

          -  BMI (body mass index) below 35 kg/m^2

        Exclusion Criteria:

          -  Use within the last 3 months prior to visit 1 (screening) of any antidiabetic glucose
             lowering drug other than insulin/insulin analogues

          -  Subjects with regular use of acetaminophen who are not willing to use another
             analgetic during CGM (Continuous Glucose Monitoring) periods

          -  Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronary
             arterial bypass graft or angioplasty within 24 weeks prior to visit 1

          -  Recurrent severe hypoglycemia (more than one severe hypoglycemic event during the last
             12 months) or hypoglycemia unawareness or hospitalization for diabetic ketoacidosis
             during the previous 6 months
Clinical trial NCT00577824 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, exenatide, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes.

          -  Has been treated by sulfonylurea (SU) alone, SU and biguanide, or SU and
             thiazolidinedione for at least 90 days prior to study start. In a patient receiving SU
             alone, the dose must be within the dose range from maximum maintenance dose to maximum
             approved dose. The patients with concomitant use of alpha glucosidase inhibitors
             (acarbose, voglibose or miglitol) or meglitinide derivatives (mitiglinide or
             nateglinide) can be included in this study, but these drugs must be discontinued at
             study start.

          -  Have HbA1c 7.0% to 10% at study start.

          -  Have a body weight >=50 kg.

        Exclusion Criteria:

          -  Have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication at the time of study entry.

          -  Have participated in this study previously or any other study using exenatide or
             glucagon-like peptide-1 (GLP-1) analogs within the last 90 days.

          -  Have been treated with any exogenous insulin within 90 days before study start.

          -  Have been continuously treated with any drug that directly affects gastrointestinal
             motility for more than a total of 21 days in the 90 days prior to study start.

          -  The combination therapy of sulfonylurea, biguanide and thiazolidinedione is not
             allowed.
Clinical trial NCT00486031 (phase 3, status: completed)
Conditions: inflammatory bowel disease, ulcerative colitis
ICD codes: M06.4, G61.89, G61.9, M35.81, G61.81, K75.9, M27.2, K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: balsalazide disodium
SMILES: OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has a documented history of UC and is either in remission or currently
             presents with mildly to moderately active UC symptoms as determined by the
             investigator upon subject interview of UC symptoms, (e.g., urgency, bowel frequency,
             and rectal bleeding). Additionally, the diagnosis of UC must be confirmed by past
             flexible sigmoidoscopy/colonoscopy which may include colonic mucosal pathological
             findings on biopsy consistent with UC.

          -  Subject is capable and willing to comply with all study procedures.

        Exclusion Criteria:

          -  Subject has a history of allergy or intolerance to aspirin, mesalamine or other
             salicylates.

          -  Subject has participated in an investigational drug or device study, other than a
             previous balsalazide disodium tablet trial (i.e., BZUC3002 or BZUC3003), within 30
             days of entering the current study.

          -  Subject discontinued from a previous balsalazide disodium tablet study due to study
             drug-related AE(s), including UC flare or associated symptoms that were perceived by
             the subject/investigator as being caused by study drug.

          -  Subject has had any prior bowel surgery, except appendectomy and cholecystectomy.

          -  Subject has unstable cardiovascular, coagulopathy, or pulmonary disease.

          -  Regular use of nonsteroidal anti-inflammatory drugs (NSAIDS) except cardioprotective
             ASA (i.e., less than or equal to 162 mg ASA per day).

          -  Subject has a history of human immunodeficiency virus (HIV) or hepatitis (B and C).
             Subjects with a history of hepatitis B and C will be eligible provided the screening
             LFTs are within normal limits.
Clinical trial NCT01535417 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: shinbaro capsule, celebrex
SMILES: CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  age between 35 and 80

          -  diagnosed with Knee OA based on criteria of ACR and showed ont through I ~ III of
             Kellgren Stage on radiography

          -  wuffered constantly with Knee OA for more than 6 months prior to begining the study

          -  scored more than 30 on total WOMAC scale

        Exclusion Criteria:

          -  had other comorbid orthopedic disease

          -  had OA of index knee from significant trauma or surgery
Clinical trial NCT01191255 (phase 3, status: completed)
Conditions: hyperphosphatemia, kidney failure
ICD codes: N19, T86.12, N17.8, N17.9, O90.4, N99.0, N17.0
Drugs: ferric citrate, ca acetate, sevelamer carbonate, placebo
SMILES: [Ca++].CC([O-])=O.CC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males or non-pregnant, non-breast-feeding females

          2. Age ≥18 years

          3. On thrice-weekly hemodialysis or on peritoneal dialysis for at least the previous
             three months prior to Screening

          4. Serum phosphorus ≥6.0 mg/dL for study entry

          5. Taking less than 3-18 pills/day of current phosphate binder

          6. Willing to be discontinued from current phosphate binder(s) and initiated on ferric
             citrate

          7. Willing and able to give informed consent

          8. Life expectancy >1 year

        Exclusion Criteria:

          1. Parathyroidectomy within six months prior to Screening

          2. Actively symptomatic gastrointestinal bleeding or inflammatory bowel disease

          3. History of multiple drug allergies or intolerances

          4. History of malignancy in the last five years (treated cervical or non-melanomatous
             skin cancer may be permitted if approved by CCC)

          5. Previous intolerance to oral ferric citrate

          6. Intolerance to oral iron-containing products

          7. Psychiatric disorder that interferes with the patient's ability to comply with the
             study protocol

          8. Inability to tolerate oral drug intake

          9. Intolerance to calcium acetate and sevelamer carbonate

         10. Any other medical condition that renders the patient unable to or unlikely to complete
             the trial or that would interfere with optimal participation in the trial or produce
             significant risk to the patient

         11. Receipt of any investigational drug within 30 days of Screening Visit (Visit 0)

         12. Inability to cooperate with study personnel or history of noncompliance

         13. Unsuitable for this trial per Investigator's clinical judgment.
Clinical trial NCT00147589 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: eplerenone
SMILES: [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)C[C@H]1O[C@@]11[C@@]2([H])[C@@H](CC2=CC(=O)CC[C@]12C)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  6-16 years old male and female

          -  Systolic blood pressure greater than or equal to the 95th percentile for age, gender,
             and height, measured on at least 3 separate occasions

        Exclusion Criteria:

          -  K/DOQI classification of stages of chronic kidney disease equal to or greater than 3

          -  Serum or whole blood potassium > 5.5 mEq/L
Clinical trial NCT00567996 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: indacaterol 150 μg, salmeterol 50 μg, placebo to indacaterol, placebo to salmeterol
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

        Clinical diagnosis of moderate to severe Chronic Obstructive Pulmonary Disease (COPD) as
        per the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2006 Guidelines
        (mandatory) and including:

          -  Smoking history of at least 20 pack years

          -  Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) < 80% predicted and
             >or= 30% of predicted normal value

          -  Post-bronchodilator FEV1/FVC < 70%

        ("Post" defined as within 30 minutes of inhalation of 400 µg salbutamol)

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women and women of child-bearing potential UNLESS they
             meet pre-specified definitions of post-menopausal or are using pre-specified
             acceptable methods of contraception

          -  Hospitalisation for COPD exacerbation in the 6 weeks prior to Visit 1 or during run-in

          -  Patients requiring oxygen therapy for chronic hypoxemia (typically >15h/day)

          -  Respiratory tract infection within 6 weeks prior to Visit 1 and during the run-in
             period

          -  Concomitant pulmonary disease

          -  Asthma history (eosinophils > 400/mm3; symptoms prior to age 40). Includes history of
             childhood asthma

          -  History of long QTc syndrome or QTc interval > 450 ms for males and >470 ms for
             females

          -  Patients who have a clinically significant condition or a clinically relevant
             laboratory abnormality

          -  History of reactions to sympathomimetic amines or inhaled medication

          -  Inability to use the dry powder devices or perform spirometry

          -  Irregular day/night, wake/sleep cycles, e.g. shift workers

          -  Certain medications for COPD and allied conditions such as long acting bronchodilators
             must not be used prior to Visit 1 and for a pre-specified minimum washout period

          -  Patients unable or unwilling to complete a patient diary

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00297102 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: roflumilast, placebo
SMILES: FC(F)OC1=C(OCC2CC2)C=C(C=C1)C(=O)NC1=C(Cl)C=NC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  COPD patients having at least one exacerbation within last year

          -  FEV1/FVC ratio (post-bronchodilator) ≤ 70%

          -  FEV1 (post-bronchodilator) ≤ 50% of predicted

        Main Exclusion Criteria:

          -  COPD exacerbation not resolved at first baseline visit

          -  Diagnosis of asthma and/or other relevant lung disease
Clinical trial NCT00702949 (phase 3, status: completed)
Conditions: breast cancer, hot flashes
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Meeting 1 of the following criteria:

               -  History of breast cancer (currently without malignant disease)

               -  No history of breast cancer, but patient wishes to avoid estrogen due to a
                  perceived increased risk of breast cancer

          -  Bothersome hot flashes (defined by their occurrence ≥ 28 times per week and of
             sufficient severity to make the patient desire therapeutic intervention)

          -  Presence of hot flashes for ≥ 1 month prior to study entry

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Life expectancy ≥ 6 months

          -  Able to complete questionnaire(s) by themselves or with assistance

          -  Women of childbearing potential not eligible (per the judgment of the attending
             clinician)

          -  Serum creatinine ≤ 1.5 times upper limit of normal

        PRIOR CONCURRENT THERAPY:

          -  No prior gabapentin or pregabalin

          -  More than 4 weeks since prior and no concurrent antineoplastic chemotherapy,
             androgens, estrogens, or progestational agents

               -  Vaginal estrogen is allowed if used for the past month and not planned to be
                  discontinued

          -  Concurrent adjuvant targeted therapy (i.e., lapatinib, trastuzumab [Herceptin®])
             allowed in patients with no evidence of disease

          -  Concurrent tamoxifen, raloxifene, or aromatase inhibitors on a constant dose for at
             least 4 weeks allowed provided the medication will not be stopped during the study
             period

          -  No concurrent or planned use of other agents for hot flashes except for any of the
             following:

               -  Stable dose of vitamin E is allowed as long as agent was started > 30 days prior
                  to study initiation and is to be continued throughout the study period

               -  Soy is allowed, if it is planned to be continued at the same dose during the
                  study period

               -  Stable dose of antidepressants is allowed as long as it was started > 30 days
                  prior to study initiation and is to be continued at a stable dose throughout the
                  study period
Clinical trial NCT01763827 (phase 3, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: ezetimibe
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female ≥ 18 to ≤ 80 years of age

          -  National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III)
             Framingham risk score of 10% or less

          -  Fasting LDL-C ≥ 100 mg/dL (2.6 mmol/L) and <190 mg/dL

          -  Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)

        Exclusion Criteria:

          -  History of coronary heart disease

          -  New York Heart Association (NYHA) III or IV heart failure

          -  Uncontrolled cardiac arrhythmia

          -  Uncontrolled hypertension

          -  Diabetes mellitus (Type 1 diabetes, poorly controlled type 2 diabetes)

          -  Uncontrolled hypothyroidism or hyperthyroidism
Clinical trial NCT00662740 (phase 3, status: terminated)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: tiotropium/salmeterol qd, placebo, salmeterol, tiotropium/salmeterol qd+ salmeterol, tiotropium
SMILES: OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1, [H][C@]12O[C@@]1([H])[C@]1([H])C[C@@]([H])(C[C@@]2([H])[N+]1(C)C)OC(=O)C(O)(C1=CC=CS1)C1=CC=CS1
Eligibility criteria:

        Inclusion criteria:

        Main:

        Diagnosis of COPD Post-bronchodilator FEV1<80% predicted and FEV1/FVC<70% predicted

        Exclusion criteria:

        Main:

        Significant other diseases then COPD Recent MI Unstable or life-threatening arrythmia
        requiring intervention or change in drug therapy Hospitalisation for cardiac failure in
        past year History of asthma
Clinical trial NCT00707980 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: vortioxetine
SMILES: CC1=CC=C(SC2=CC=CC=C2N2CCNCC2)C(C)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Has completed the double blind treatment period of either study Lu AA21004_304
             (NCT00672620) or LuAA21004_305 (NCT00735709) immediately prior to enrollment in the
             extension study (ie, the baseline visit is the same visit as the completion visit of
             the double blind treatment of the preceding protocol).

          -  Suffers from a major depressive episode as the primary diagnosis according to
             Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision
             (DSM-IV-TR) criteria (classification code 296.xx) at entry into the prior Lu
             AA21004_304 or Lu AA21004_305 study.

        Exclusion Criteria:

          -  In addition to meeting the exclusion criteria for studies Lu AA21004_304 or Lu
             AA21004_305 at the time of enrollment into those studies respectively, with the
             exception of the criteria prohibiting previous exposure to Lu AA21004 and
             investigational drugs, and the criteria prohibiting patients with increased
             intraocular pressure, or risk of acute narrow-angle glaucoma, the following exclusion
             criteria apply:

               -  Has Major Depressive Disorder for whom other psychiatric disorders (mania,
                  bipolar disorder, schizophrenia, or any psychotic disorder) have been diagnosed
                  during the prior study.

               -  The participant, in the investigator's opinion, has a significant risk of suicide
                  and/or a score of ≥5 points on item 10 (suicidal thoughts) of the Montgomery
                  Åsberg Depression Rating Scale.

               -  The participant, in the opinion of the investigator, is unlikely to comply with
                  the clinical study protocol or is unsuitable for any reason.

               -  Has a clinically significant moderate or severe ongoing adverse event related to
                  study medication from the prior study.

               -  Has used/uses disallowed concomitant medication.
Clinical trial NCT00394901 (phase 3, status: completed)
Conditions: neuralgia, postherpetic
ICD codes: B02.22
Drugs: placebo, pregabalin, pregabalin, pregabalin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Visual Analogue Scale (VAS) of pain is higher than 40 mm.

          -  Pain is sustained for more than 3 months after healing of herpes zoster skin rash.

        Exclusion Criteria:

          -  Malignancy within the past 2 years.

          -  Patients who have undergone neurolytic or neurosurgical therapy for postherpetic
             neuralgia.

          -  Creatinine clearance </= 30 mL/min (estimated from serum creatinine, body weight, age,
             and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).

          -  Patients having other severe pain which may impair the self assessment of the pain due
             to postherpetic neuralgia.

          -  Skin conditions in the affected dermatome that could alter sensation.
Clinical trial NCT00449930 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: sitagliptin phosphate, comparator: metformin hydrochloride
SMILES: N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        General Inclusion Criteria:

          -  Patient has type 2 diabetes mellitus (T2DM)

          -  Patient is inadequately controlled and not on treatment with insulin or oral
             antihyperglycemic therapy

        General Exclusion Criteria:

          -  Patient has a history of type 1 diabetes mellitus or history of ketoacidosis

          -  Patient was on antihyperglycemic therapy (insulin or oral) within the prior 4 months